COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS

(19)

(11)

EP 2 330 894 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	19.04.2017 Bulletin 2017/16

(45)	Mention of the grant of the patent:
	21.12.2016 Bulletin 2016/51

(21)	Application number: 09812248.4

(22)	Date of filing: 03.09.2009

(51)

International Patent Classification (IPC):

C07C 235/16^(2006.01)
C07C 255/57^(2006.01)
C07C 311/19^(2006.01)
C07C 323/62^(2006.01)
C07D 213/30^(2006.01)
C07D 277/56^(2006.01)
C07D 307/84^(2006.01)
A01N 37/18^(2006.01)
A61K 31/16^(2006.01)

C07C 237/22^(2006.01)
C07C 311/16^(2006.01)
C07C 317/44^(2006.01)
C07D 209/48^(2006.01)
C07D 231/56^(2006.01)
C07D 295/14^(2006.01)
C07D 409/12^(2006.01)
A61K 31/00^(2006.01)

(86)	International application number:
	PCT/US2009/055952

(87)	International publication number:
	WO 2010/028192 (11.03.2010 Gazette 2010/10)

(54)	COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS ZUSAMMENSETZUNGEN MIT 6-AMINOHEXANSÄUREDERIVATEN ALS HDAC-HEMMER COMPOSITIONS COMPRENANT DES DÉRIVÉS D ACIDE 6-AMINOHEXANOÏQUE UTILISÉES COMME INHIBITEURS DE HDAC

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30)

Priority:

03.09.2008 US 93927 P
07.11.2008 US 112556 P

(43)	Date of publication of application:
	15.06.2011 Bulletin 2011/24

(73)	Proprietor: BioMarin Pharmaceutical Inc.
	Novato, CA 94949 (US)

(72)	Inventors:
	RUSCHE, James, R. Framingham Massachusetts 01702 (US) PEET, Norton, P. North Andover Massachusetts 01845-2117 (US) HOPPER, Allen, T. Katonah New York 10536 (US)

(74)	Representative: D Young & Co LLP
	120 Holborn London EC1N 2DY London EC1N 2DY (GB)

(56)

References cited: :

WO-A1-2006/005955
WO-A1-2009/045440
US-A1- 2006 166 990

WO-A1-2006/102760
WO-A2-2007/100657
US-B2- 6 710 060

C. J. CHOU ET AL.: "Pimelic Diphenylamide 106 Is a Slow, Tight-binding Inhibitor of Class I Histone Deacetylases", J. BIOL. CHEM., vol. 283, no. 51, 19 December 2008 (2008-12-19), pages 35402-35409, XP002680733,
M. Rai et al.: "HDAC Inhibitors Correct Frataxin Deficiency in a Friedreich Ataxia Mouse Mode", PLoS ONE, vol. 3, no. 4, E1958, 9 April 2008 (2008-04-09), pages 1-8, XP002680734, Retrieved from the Internet: URL:www.plosone.org/article/fetchArticle.a ction?articleURI=info:doi/10.1371/journal. pone.0001958 [retrieved on 2012-07-25]
D. HERMAN ET AL.: "Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia", NATURE CHEMICAL BIOLOGY, vol. 2, no. 10, October 2006 (2006-10), pages 551-558, XP002680735, ISSN: 1552-4450, DOI: 10.1038/nchembio815
PARIS M ET AL: "Histone deacetylase inhibitors: From bench to clinic", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 51, no. 6, 27 March 2008 (2008-03-27) , pages 1505-1529, XP002495888, ISSN: 0022-2623, DOI: 10.1021/JM7011408 [retrieved on 2008-02-05]

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).